Fountzilas, G., Giannoulatou, E., Alexopoulou, Z., Zagouri, F., Timotheadou, E., Papadopoulou, K., . . . Kotoula, V. (2016). TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget.
Style de citation ChicagoFountzilas, George, et al. "TP53 Mutations and Protein Immunopositivity May Predict for Poor Outcome but Also for Trastuzumab Benefit in Patients With Early Breast Cancer Treated in the Adjuvant Setting." Oncotarget 2016.
Style de citation MLAFountzilas, George, et al. "TP53 Mutations and Protein Immunopositivity May Predict for Poor Outcome but Also for Trastuzumab Benefit in Patients With Early Breast Cancer Treated in the Adjuvant Setting." Oncotarget 2016.